Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CHAT | P28329 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28449233 | 0.96 | — | — | |
| SCHEMBL9040376 | 0.96 | SLC22A2 (0.47) | SLC22A2SLC22A1SLC22A3SLC6A4CHAT | |
| SCHEMBL27002 | 0.96 | — | — | |
| SCHEMBL11139484 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL547128 | 0.92 | — | — | |
| Bromide SCHEMBL557818 | 0.92 | — | — | |
| Ethane SCHEMBL22264538 | 0.92 | — | — | |
| Water SCHEMBL20339640 | 0.92 | SLC22A2 (0.45) | SLC22A2SLC22A1SLC22A3SLC6A4CHAT | |
| SCHEMBL20543430 | 0.92 | — | — | |
| Fluoride SCHEMBL21633960 | 0.92 | SLC22A2 (0.45) | SLC22A2SLC22A1SLC22A3SLC6A4CHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102860-A1 | ENGINEERED CELLS FOR THERAPY | SHORELINE BIOSCIENCES, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4359541-A2 | ENGINEERED CELLS FOR THERAPY | Editas Medicine, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240117383-A1 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | EDITAS MEDICINE, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4346877-A2 | ENGINEERED CELLS FOR THERAPY | Shoreline Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023220207-A2 | GENOME EDITING OF CELLS | EDITAS MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220206-A2 | GENOME EDITING OF B CELLS | EDITAS MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230227856-A1 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | BLUEROCK THERAPEUTICS LP | 2023-07-20 | — | — | US | disclosed |
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2023-07-06 | — | — | US | disclosed |
| WO-2023097316-A1 | ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOF | EDITAS MEDICINE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2021123229-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | GENIE BIOTECH UK LTD. (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127594-A1 | ENGINEERED CELLS FOR THERAPY | EDITAS MEDICINE, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3823633-A1 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | Editas Medicine, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020006423-A9 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | EDITAS MEDICINE, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200256862-A1 | FUNCTIONALIZED SOLID SUPPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-08-13 | — | — | US | disclosed |
| US-20200190513-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | EDITAS MEDICINE, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3615672-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | Editas Medicine, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3565895-A1 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | Editas Medicine, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018201086-A1 | METHODS AND SYSTEMS FOR ANALYZING GUIDE RNA MOLECULES | EDITAS MEDICINE, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018126176-A1 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | EDITAS MEDICINE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212216-A1 | SYNTHESIS OF LACTONE DERIVATIVES AND THEIR USE IN THE MODIFICATION OF PROTEINS | AGL, PGLS, DDOST | SLC22A2 3949/4885SLC22A1 3512/4885SLC22A3 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.